Marrying CRISPR with immuno-oncology to defeat remote tumors by Arlene Weintraub Monday, October 14, 2019 Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.
Kleiner, GV drive gene editing startup Trucode to $34M round by Nick Paul Taylor Tuesday, September 10, 2019 Trucode will use the money to advance gene editing assets designed to correct the mutations behind diseases including cystic fibrosis.
New discovery could open up PARP inhibitors to more patients by Amirah Al Idrus Wednesday, July 24, 2019 UT Southwestern researchers uncovered a mechanism by which PARP inhibitors attack cancer, suggesting they could be used in more patients.
Yale, Mayo tap Biofourmis for digital heart failure endpoints by Amirah Al Idrus Wednesday, July 17, 2019 The partners will study patient-focused endpoints alongside so-called “hard outcomes" that have traditionally served as endpoints in clinical trials.
FDA contributes to hunt for new heart failure endpoints by Nick Paul Taylor Tuesday, July 16, 2019 The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.
New insight into a struggling AZ cancer drug could expand its use by Arlene Weintraub Friday, May 17, 2019 Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.
Could a glaucoma drug also fight obesity? by Angus Liu Friday, August 10, 2018 A Yale University team found two potential methods for preventing fat particles from slipping into tissues.
New discoveries in ALS and malaria—News of Note by Arlene Weintraub Monday, July 16, 2018 The week’s biotech news included a mutation-targeting treatment for ALS and a malaria vaccine targeting a transmission protein.
Could even more cancer patients benefit from PARP inhibitors? by Arlene Weintraub Monday, July 16, 2018 The mechanism by which PARP inhibitors in BRCA-mutated cancers work could make them applicable to many more cancer types.
Editing genes with a more precise alternative to CRISPR by Arlene Weintraub Thursday, November 16, 2017 A Yale team has developed an alternative gene-editing technology that they say replaces CRISPR’s “hacksaw” effect with a more precise “scalpel.”
